Patents by Inventor Daniel Vargas Correia

Daniel Vargas Correia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR THE PRODUCTION OF TCR GAMMA DELTA + T CELLS
    Publication number: 20210361708
    Abstract: The present invention relates to novel methods for the isolation and the selective ex vivo expansion of V32? TCRy6+ T cells and to their clinical application.
    Type: Application
    Filed: May 4, 2021
    Publication date: November 25, 2021
    Inventors: Diogo Antonio Remechido ANJOS, Daniel Vargas CORREIA, Afonso Rocha MARTINS DE ALMEIDA
  • METHODS FOR THE PRODUCTION OF TCR GAMMA DELTA + T CELLS
    Publication number: 20210361707
    Abstract: The present invention relates to novel methods for the isolation and the selective ex vivo expansion of V32? TCRy6+ T cells and to their clinical application.
    Type: Application
    Filed: May 4, 2021
    Publication date: November 25, 2021
    Inventors: Diogo Antonio Remechido ANJOS, Daniel Vargas CORREIA, Afonso Rocha MARTINS DE ALMEIDA
  • Methods for the production of TCR?? T cells
    Patent number: 11166983
    Abstract: The present invention relates to novel methods for the isolation and the selective ex vivo expansion of V?2? TCR??+T cells and to their clinical application.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: November 9, 2021
    Assignee: LYMPHACT—LYMPHOCYTE ACTIVATION TECHNOLOGIES, S.A.
    Inventors: Diogo Antonio Remechido Anjos, Daniel Vargas Correia, Anfonso Rocha Martins De Almeida
  • METHODS FOR THE PRODUCTION OF TCR GAMMA DELTA + T CELLS
    Publication number: 20180169147
    Abstract: The present invention relates to novel methods for the isolation and the selective ex vivo expansion of V?2? TCR??+T cells and to their clinical application.
    Type: Application
    Filed: June 8, 2016
    Publication date: June 21, 2018
    Inventors: Diogo Antonio Remechido ANJOS, Daniel Vargas CORREIA, Anfonso Rocha MARTINS DE ALMEIDA
  • Cell line of lymphocytes comprising gamma-delta T cells, composition and production method thereof
    Patent number: 9499788
    Abstract: The present invention relates to a cell line of lymphocytes comprising ?? T cells, composition and production method thereof, and medical use namely for the use in medicine, namely in cancer immunotherapy. The cell line comprise a sample of human peripheral blood V?1+ ?? T cells expressing functional natural cytotoxicity receptors (NCRs). These V?1+ NCR+ T lymphocytes can directly mediate killing of leukemia cell lines and chronic lymphocytic leukemia patient neoplastic cells. The present invention shows that human V?1+ NCR+ T cells can be differentiated and expanded from total ?? peripheral blood lymphocytes (PBLs), upon regular in vitro or ex vivo stimulation with ??TCR agonists and ?c-family cytokines. This subset surprisingly expresses NKp30, NKp44 and NKp46, and high levels of Granzyme B that associate with highly enhanced cytotoxicity against lymphoid leukemias.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: November 22, 2016
    Assignee: INSTITUTO DE MEDICINA MOLECULAR
    Inventors: Bruno Miguel de Carvalho e Silva Santos, Daniel Vargas Correia
  • CELL LINE OF LYMPHOCYTES COMPRISING GAMMA-DELTA T CELLS, COMPOSITION AND PRODUCTION METHOD THEREOF
    Publication number: 20140141513
    Abstract: The present invention relates to a cell line of lymphocytes comprising ?? T cells, composition and production method thereof, and medical use namely for the use in medicine, namely in cancer immunotherapy. The cell line comprise a sample of human peripheral blood V?1+ ?? T cells expressing functional natural cytotoxicity receptors (NCRs). These V?1+ NCR+ T lymphocytes can directly mediate killing of leukemia cell lines and chronic lymphocytic leukemia patient neoplastic cells. The present invention shows that human V?1+ NCR+ T cells can be differentiated and expanded from total ?? peripheral blood lymphocytes (PBLs), upon regular in vitro or ex vivo stimulation with ??TCR agonists and ?c-family cytokines. This subset surprisingly expresses NKp30, NKp44 and NKp46, and high levels of Granzyme B that associate with highly enhanced cytotoxicity against lymphoid leukemias.
    Type: Application
    Filed: May 21, 2012
    Publication date: May 22, 2014
    Applicant: INSTITUTO DE MEDICINA MOLECULAR
    Inventors: Bruno Miguel De Carvalho Silva Santos, Daniel Vargas Correia